Biogen (BIIB) to present new late-breaking Litifilimab Phase 2 AMETHYST data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology annual meeting
Importance
Level 1
- Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)
- Litifilimab was recently granted Breakthrough Therapy Designation by the FDA for CLE; AMETHYST Part A results supported the designation
- CLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement when left untreated, and has no targeted treatment option
#BIOGEN IDEC INC#BIIB.US#FDA#EQUITIES#EU SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#BIOGEN INC#BIIB#US EQUITIES